FDA clears third emergency COVID-19 vaccine from J&JThe FDA has approved emergency use of a third COVID-19 vaccine from Johnson & Johnson’s Janssen Biotech unit, Share XFDA clears third emergency COVID-19 vaccine from J&Jhttps://pharmaphorum.com/news/fda-clears-third-emergency-covid-19-vaccine-from-jj/
A history of Johnson & JohnsonSet up by three brothers back in 1886, Johnson & Johnson continues to keep evolving Share XA history of Johnson & Johnsonhttps://pharmaphorum.com/views-analysis-sales-marketing/a-history-of-johnson-johnson/
FDA reviewer backs J&J COVID jab for emergency OKJohnson & Johnson’s one-shot coronavirus vaccine is due to be reviewed by an FDA advisory committee on Friday, Share XFDA reviewer backs J&J COVID jab for emergency OKhttps://pharmaphorum.com/news/fda-reviewer-backs-jj-covid-jab-for-emergency-ok/
Early data back J&J and AC Immune’s Alzheimer’s jabShares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s Share XEarly data back J&J and AC Immune’s Alzheimer’s jabhttps://pharmaphorum.com/news/early-data-back-jj-and-ac-immunes-alzheimers-jab/
EMA approves AZ’s COVID-19 vaccine – including for over-65sThe EMA has approved AstraZeneca’s COVID-19 vaccine for use in the EU in all adults aged over 18, Share XEMA approves AZ’s COVID-19 vaccine – including for over-65shttps://pharmaphorum.com/news/ema-approves-azs-covid-19-vaccine-including-for-over-65s/
AZ says Calquence is a safer drug than ImbruvicaAstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment Share XAZ says Calquence is a safer drug than Imbruvicahttps://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/
ViiV/J&J’s long-acting HIV regimen finally approved in USThe FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the Share XViiV/J&J’s long-acting HIV regimen finally approved in UShttps://pharmaphorum.com/news/fda-finally-approves-viiv-jjs-long-acting-hiv-regimen/
One in 11 over-65s unwilling to take COVID-19 shotOne in 11 adults aged over 65 have reported a lack of willingness to receive a COVID-19 vaccine, Share XOne in 11 over-65s unwilling to take COVID-19 shothttps://pharmaphorum.com/news/one-in-11-older-patients-unwilling-to-take-covid-19-shot/
J&J’s Darzalex Faspro is first US therapy for rare blood disorderJohnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain Share XJ&J’s Darzalex Faspro is first US therapy for rare blood disorderhttps://pharmaphorum.com/news/jjs-darzalex-faspro-is-first-us-therapy-for-rare-blood-disorder/